ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

Jun 2, 2026read at BioPharma Dive ↗

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

source

Reporting by BioPharma Dive. The original article may no longer be reachable at its published URL.

read at BioPharma Dive ↗

sharex / twitter linkedin

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

BioPharma DiveJun 21 min read

save

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

Jun 2, 2026read at BioPharma Dive ↗

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

source

Reporting by BioPharma Dive. The original article may no longer be reachable at its published URL.